Cao Fei launches tender offer for Hubei Jumpcan shares

Hubei Jumpcan Pharmaceutical (SSE:600566) has announced that Mr. Cao Fei is commencing a tender offer to acquire 350,841,357 shares, representing 38.06% of the company's total share capital. The offer period runs from June 18, 2025, to July 17, 2025, with a cash payment of CNY 26.93 per share. This move follows Mr. Cao Fei's acquisition of a 10.10% stake in Jiangsu Jichuan Holdings Group for CNY 10.10 million, solidifying his position as a joint actual controller of Hubei Jumpcan. The tender offer is triggered by Mr. Cao Fei's indirect holding of 56.07% of the company's shares through Jichuan Holdings and Xizang Jichuan Enterprise Management. The offer aims to fulfill a statutory obligation and does not intend to delist the company.